Close Menu

NEW YORK – Liquid biopsy firm Inivata said today that it is launching a prospective clinical study with France's Centre Léon Bérard cancer center to test whether its InVisionFirst-Lung test can get patients on appropriate treatment more quickly than tissue-based genetic testing.

The randomized Phase III interventional trial is called LIquid Biopsy for the Early detection of LUng cancer LEsion (LIBELULE). Investigators plan to enroll at least 286 patients across 17 clinical sites in France.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.